Practical Suggestions on Intravenous Iloprost in Raynaud's Phenomenon and Digital Ulcer Secondary to Systemic Sclerosis: Systematic Literature Review And Expert Consensus

Systemic sclerosis (SSc) is an autoimmune chronic disease characterized by vascular impairment, immune dysfunction and collagen deposition. Raynaud's phenomenon (RP) and digital ulcers (DU) are prominent features of SSc. Intravenous (IV) iloprost (ILO), according to the recently updated EULAR recommendations, is indicated for RP after failure of oral therapy. Moreover, IV ILO could be useful in DU healing. IV ILO is currently available mainly on the European market approved for RP secondary to SSc with 3 –5 days infusion cycle.

Source: Seminars in Arthritis and Rheumatism - April 4, 2018 Category: Rheumatology Authors: Francesca Ingegnoli, Tommaso Schioppo, Yannick Allanore, Roberto Caporali, Michele Colaci, Oliver Distler, Daniel E. Furst, Nicolas Hunzelmann, Florenzo Iannone, Dinesh Khanna, Marco Matucci-Cerinic Source Type: research